Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report.
The report “Colorectal Cancer: Drug Pipeline Analysis and Market Forecasts to 2016” available at http://www.reportbuyer.com/
The report estimates the colorectal cancer (CRC) market as being worth $6 billion in 2009 with a projected CAGR of 9.8% and projected market value to exceed $11.6 billion in 2016. The replacement of chemotherapies by target therapies in adjuvant treatments and neo adjuvant therapies has boosted the sales of CRC therapeutics market.
GlobalData has found that products for colorectal cancer in developmental pipeline are strong with over 158 molecules in various phases of clinical development. There are more than 77 first-in-class molecules in different stages of clinical development. These molecules have a distinct advantage over the current market players and display robustness in the CRC pipeline. Chemotherapy with or without combinational targeted therapies may improve the symptoms and prolong the life of the cancer patients. Huge research activities in combinational targeted therapies are ongoing in the R&D sectors.
Aflibercept, Recentin, OncoVax, TroVax and Brivanib are the most promising molecules currently in the pipeline. These targeted drugs from a new class of therapies hold a promise to add value to CRC market in the near future and may strongly compete with current market players on the basis of better efficacy and safety profile leading to overall patient and physician satisfaction.
The report “Colorectal Cancer: Drug Pipeline Analysis and Market Forecasts to 2016” is available from Report Buyer at:
http://www.reportbuyer.com/
Report Buyer product ID: GDA00733
About Report Buyer.
Report Buyer
http://www.reportbuyer.com/
